Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
For metastatic/advanced NSCLC patients who do not have targetable mutations, either
immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in
combination with platinum doublet chemotherapy is now a standard of care. However, still
about half of the patients do not benefit due to treatment resistance. It is therefore
critically important to find novel therapies and combinations to benefit patients who have
failed or are intolerant to 1st line immunotherapy.
This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be
an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive
inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also
known as AKT) in cancer patients. Importantly, evidence from preclinical studies has
demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of
chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase
(PI3'K)-AKT activity.
Phase:
Phase 2
Details
Lead Sponsor:
Jun Zhang, MD, PhD University of Kansas Medical Center